Sponsor:
Ryvu Therapeutics SA
Code:
NCT06268574
Conditions
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RVU120
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-23. This information was provided to ClinicalTrials.gov by Ryvu Therapeutics SA on 2025-01-22.